Advertisement


Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

2017 ESMO Congress

Advertisement

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Abstract LBA14).



Related Videos

Gynecologic Cancers

Domenica Lorusso, MD, PhD, on Cervical Cancer: Results From a Trial on Treatment Regimens

Domenica Lorusso, MD, PhD, of the National Cancer Institute of Milan, discusses neoadjuvant chemotherapy followed by surgery vs concurrent cisplatin and radiation therapy in patien...

Breast Cancer

Judy E. Garber, MD, MPH, on Triple-Negative Breast Cancer: An Update

Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, offers expert perspectives on the role of PARP inhibitors in treating triple-negative breast cancer.

Head and Neck Cancer

Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial

Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metast...

Kidney Cancer

Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metas...

Pancreatic Cancer

David A. Tuveson, MD, PhD, on Progress in Pancreatic Cancer: Expert Perspective

David A. Tuveson, MD, PhD, of Cold Spring Harbor Laboratory, discusses the most lethal of cancers. Although treatments are improving, the challenges are great, including early dete...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.